Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
O Ogbuagu, S Segal-Maurer, W Ratanasuwan… - The Lancet …, 2023 - thelancet.com
Background Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-
acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety …
acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety …
Week 240 efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1
JA Aberg, B Shepherd, M Wang, JV Madruga… - Infectious Diseases and …, 2023 - Springer
Introduction Efficacy and safety of the attachment inhibitor fostemsavir+ optimized
background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 …
background therapy (OBT) were evaluated through 48 and 96 weeks in the phase 3 …
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants
M Aoki, H Aoki-Ogata, H Bulut, H Hayashi… - Science …, 2023 - science.org
Nuclear localization signal (NLS) of HIV-1 integrase (IN) is implicated in nuclear import of
HIV-1 preintegration complex (PIC). Here, we established a multiclass drug-resistant HIV-1 …
HIV-1 preintegration complex (PIC). Here, we established a multiclass drug-resistant HIV-1 …
Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report
MC Puertas, G Ploumidis, M Ploumidis… - The Lancet …, 2020 - thelancet.com
Background In 2019, WHO reported that the prevalence of HIV-1 drug resistance to first-line
regimens of non-nucleoside reverse transcriptase inhibitors is increasing in countries with a …
regimens of non-nucleoside reverse transcriptase inhibitors is increasing in countries with a …
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
T Clemente, L Galli, R Lolatto, R Gagliardini, F Lagi… - BMJ open, 2024 - bmjopen.bmj.com
Purpose The PRESTIGIO Registry was established in 2017 to collect clinical, virological and
immunological monitoring data from people living with HIV (PLWH) with documented four …
immunological monitoring data from people living with HIV (PLWH) with documented four …
Week 96 genotypic and phenotypic results of the fostemsavir phase 3 BRIGHTE study in heavily treatment-experienced adults living with multidrug-resistant HIV-1
M Gartland, P Cahn, E DeJesus, RS Diaz… - Antimicrobial agents …, 2022 - Am Soc Microbiol
In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-
resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained …
resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained …
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database
F Lombardi, A Giacomelli, D Armenia, A Lai… - International journal of …, 2021 - Elsevier
Despite successful antiretroviral therapy (ART), patients infected with human
immunodeficiency virus (HIV) can develop multi-class drug resistance (MDR). This …
immunodeficiency virus (HIV) can develop multi-class drug resistance (MDR). This …
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1
P Ackerman, M Thompson, JM Molina, J Aberg… - AIDS, 2021 - journals.lww.com
Objectives: The aim of this study was to understand how demographic and treatment-related
factors impact responses to fostemsavir-based regimens. Design: BRIGHTE is an ongoing …
factors impact responses to fostemsavir-based regimens. Design: BRIGHTE is an ongoing …
Characterization of heavily treatment-experienced people with HIV and impact on health care resource utilization in US commercial and Medicare Advantage health …
J Priest, E Hulbert, BL Gilliam… - Open Forum Infectious …, 2021 - academic.oup.com
Background This retrospective administrative claims study aimed to describe clinical
characteristics, health care resource utilization (HCRU), and costs of people with HIV (PWH) …
characteristics, health care resource utilization (HCRU), and costs of people with HIV (PWH) …
[HTML][HTML] Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals
Background We aimed at evaluating the temporal trend of drug-resistance and APOBEC
editing from HIV-DNA genotypic resistance tests (GRT) in virologically suppressed …
editing from HIV-DNA genotypic resistance tests (GRT) in virologically suppressed …